

1230 US Highway 11

Gouverneur, NY 13642

Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129 Kineret® Prior Authorization Request Form (Page 1 of 2)

Memb	Provider Information (required)						
Member Name:			Provider Name:				
Insurance ID#:			NPI#:	NPI#: Specialty:			
Date of Birth:			Office Phone:				
Street Address:			Office Fax:				
City:	State:	Zip:	Office Street Address:				
Phone:		City:	City: State:		Zip:		
	N	ledication Info	rmation (required)				
Medication Name:			Strength: Dosage Form:				
☐ Check if requesting brand			Directions for Use:				
☐ Check if request is for							
Select the diagnosis below: Moderately to severely active rheumatoid arthritis Neonatal-onset multisystem inflammatory disease (NOMID) Systemic juvenile idiopathic arthritis (SJIA) Other diagnosis:							
Select if the patient has NLRP-3 [nucleotic inflammatory synce Evidence of active Evidence of active	nultisystem inflammato is a diagnosis of NOMID de-binding domain, leuc drome-1 [CIAS1]) mutati e inflammation which inc e inflammation which inc	as confirmed by the folk ine rich family (NLR), py on cludes clinical symptoms cludes elevated acute ph	owing: rin domain containing 3 (e.g., rash, fever, arthra ase reactants (e.g., ES	gene (also	known as co	ld-induced auto-	
	e idiopathic arthritis (S. active SJIA? Yes		ollowing:				
Does the patient have history of failure, contraindication, or intolerance to a non-steroidal anti-inflammatory drug (NSAID) [e.g., Motrin (ibuprofen), Naprosyn (naproxen)]? Yes No Does the patient have history of failure, contraindication, or intolerance to a systemic glucocorticoid (e.g., prednisone)? Yes No							

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of ProAct. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Kineret_Jan_2018



1st Attempt

2nd Attempt

1230 US Highway 11 Gouverneur, NY 13642

Phone: 1-877-635-9545

Prior Authorization Fax: 1-844-712-8129

Kineret® Prior Authorization Request Form (Page 2 of 2)

Reauth	horization:
	is a reauthorization request, answer the following questions:
	e documentation the patient has had a positive clinical response to Kineret therapy? Yes No
	if Kineret will be used in combination with any of the following:
	Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
	Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)] Not in combination with a biologic DMARD or janus kinase inhibitor
	Total Combination with a biologic biviate of janus kinaseminibitor
Are there	e any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to ew?
Please no	ote: This request may be denied unless all required information is received.
	Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.
	Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.
certify, to	o the best of my knowledge, the statements and information provided on this form are factual and correct.
rovider/R	Representative (and Title): Date:
	PROACT INTERNAL USE ONLY:
linical	Review Decision
	Approved, through
	Denied (documentation attached, if necessary)
rackin	g:

Letter Mailed: